1. Home
  2. TBBK vs MLYS Comparison

TBBK vs MLYS Comparison

Compare TBBK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Bancorp Inc

TBBK

The Bancorp Inc

HOLD

Current Price

$66.98

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.82

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBBK
MLYS
Founded
1999
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.1B
IPO Year
2005
2023

Fundamental Metrics

Financial Performance
Metric
TBBK
MLYS
Price
$66.98
$26.82
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$69.00
$48.67
AVG Volume (30 Days)
403.2K
1.1M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
14.69
37.43
EPS
1.41
N/A
Revenue
$141,147,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.16
N/A
P/E Ratio
$46.62
N/A
Revenue Growth
20.85
N/A
52 Week Low
$50.29
$12.59
52 Week High
$81.65
$47.65

Technical Indicators

Market Signals
Indicator
TBBK
MLYS
Relative Strength Index (RSI) 61.76 45.70
Support Level $66.21 $26.01
Resistance Level $71.69 $31.26
Average True Range (ATR) 1.97 1.23
MACD -0.30 -0.17
Stochastic Oscillator 57.62 13.68

Price Performance

Historical Comparison
TBBK
MLYS

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: